TIGIT (Domvanalimab Biosimilar) Recombinant Monoclonal Antibody

1. The activation of PD-1 and TIGIT may exert negative regulatory effects and inhibit the immune response to cancer cells, resulting in immune escape of cancer cells. PMID: 30262800
2. These findings highlight the importance of the TIGIT/CD226/PVR axis as an immune checkpoint barrier that could hinder future "cure" strategies requiring potent HIV-specific CD8(+) T cells PMID: 28084312
3. High expression of TIGIT and Helios identifies CD4+ T cells with impaired immunological functions, primarily among patients with an advanced stage of Sezary syndrome. PMID: 27592800
4. Natural killer cells and cytotoxic T cells express both TIGIT and DNAM-1 receptors, and in certain cases their effector functions are dictated by TIGIT or DNAM-1 signaling. Agonist and antagonist antibodies targeting either TIGIT or DNAM-1 present many therapeutic options for diseases spanning from cancer to auto-immunity. (Review) PMID: 28035916
5. TIGIT contributes to functional T-cell impairment and associates with poor clinical outcome in acute myelogenous leukemia. The study suggests that blockade of TIGIT to restore T-cell function and antitumor immunity may represent a novel effective leukemia therapeutic. PMID: 26763253
6. Blimp-1 binds to the promoters of PD-1 and TIGIT and positively regulates their expression in patients with acute myeloid leukemia. PMID: 28629373
7. Data show that gastric cancer cells inhibit T-cell metabolism through CD155/TIGIT signaling. PMID: 28883004
8. Our data provide important structural and biochemical determinants responsible for the recognition of nectin-2 by TIGIT. PMID: 27978489
9. TIGIT is a powerful negative regulator of CD4(+) T cells in systemic lupus erythematosus. PMID: 28108989
10. TIGIT signaling in NK cells after MDSC coculture led to a decrease in the phosphorylation of ZAP70/Syk and ERK1/2. PMID: 27503932
11. energetic basis for the TIGIT/nectin-2 interaction and revealed that an "aromatic key" of nectin-2 is critical for this interaction, whereas variations in the lock were tolerated. PMID: 28515320
12. TIGIT-positive circulating follicular helper T cells display robust B-cell help functions: potential role in sickle cell alloimmunization. PMID: 26250578
13. implying that TIGIT exerts immunosuppressive effects by competing with DNAM-1 for the same ligand, CD155 PMID: 26842126
14. These findings identify TIGIT as a novel marker of dysfunctional HIV-specific T cells PMID: 26741490
15. This study shows that HBZ-induced TIGIT plays a pivotal role in attenuating host immune responses and shaping a microenvironment favorable to human T-cell leukemia virus type 1. PMID: 26735971
16. a novel mechanism that links TIGIT expression with NK-cell functional heterogeneity, and this mechanism might partially explain why individuals have different susceptibilities to infection, autoimmune disease, and cancer. PMID: 26171588
17. Human regulatory T cells expressing the receptors TIGIT and CD226 display widely divergent phenotypes in regard to expansion and activation. PMID: 25994968
18. TIGIT and PD-1 blockade additively increased proliferation, cytokine production, and degranulation of tumor-antigen-specific CD8 T cells and CD8 TILs. TIGIT and PD-1 regulate the expansion and function of these T cells in melanoma. PMID: 25866972
19. The results identify a bacterium-dependent, tumor-immune evasion mechanism in which tumors exploit the Fap2 protein of F. nucleatum to inhibit immune cell activity via TIGIT. PMID: 25680274
20. Findings suggest that TIGIT is a key checkpoint inhibitor of chronic antiviral and antitumor responses through impairing CD226 function when disrupting its homodimerization. PMID: 25465800
21. TIGIT/PVR ligation signaling mediates suppression of IFN-gamma production via the NF-kappaB pathway. PMID: 24817116
22. TIGIT is phosphorylated at its cytoplasmic tail after its ligation with PVR. PMID: 23154388
23. The Tim-3 pathway appears to control regulatory (Treg) and effector T cell balance via altering cell proliferation and apoptosis during hepatitis C virus infection. PMID: 22706088
24. TIGIT can inhibit T cell functions by competing with CD226 and can also directly inhibit T cells in a T cell-intrinsic manner. PMID: 22427644
25. data suggest a cis-trans receptor clustering mechanism for cell adhesion and signaling by the TIGIT/PVR complex and provide structural insights into how the PVR family of immunoregulators function PMID: 22421438
26. that soluble Vstm3 attenuates T-cell responses in vitro and in vivo PMID: 21416464
27. TIGIT exerts immunosuppressive effects by binding to poliovirus receptor and modulating cytokine production by dendritic cells. PMID: 19011627
28. a novel immunoreceptor, Washington University Cell Adhesion Molecule, which is expressed on human follicular B helper T cells, was described. PMID: 19197944
29. TIGIT counter inhibits the NK-mediated killing of tumor cells and protects normal cells from NK-mediated cytotoxicity thus providing an "alternative self" mechanism for MHC class I inhibition. PMID: 19815499

Show More

Hide All

HGNC: 26838

OMIM: 612859

KEGG: hsa:201633

STRING: 9606.ENSP00000373167

UniGene: Hs.421750